和黄药业并表提振业绩 上海医药净利同比增长25.74%

Core Viewpoint - Shanghai Pharmaceuticals reported strong financial performance for 2025, with significant growth in revenue and net profit, highlighting the company's successful business strategies and innovation efforts [1][3]. Financial Performance - The company achieved a revenue of 283.58 billion yuan, a year-on-year increase of 3.03% [1]. - The net profit attributable to shareholders reached 5.725 billion yuan, marking a 25.74% increase and setting a new record since the company's listing [1]. - Operating cash flow showed a net inflow of 6.154 billion yuan, up by 5.61% [1]. Business Segments - In the pharmaceutical commercial segment, sales revenue was 259.06 billion yuan, reflecting a 3% growth [1]. - The company expanded its pure sales network to cover 25 provinces, with eight provinces achieving sales exceeding 10 billion yuan [1]. - The innovative business segment saw significant breakthroughs, with CSO business exceeding 10 billion yuan and innovative drug services generating 53.7 billion yuan in revenue, a substantial year-on-year increase [1][2]. Industrial Segment - The pharmaceutical industrial segment reported sales revenue of 24.52 billion yuan, a growth of 3.33% [1]. - Research and development investment reached 2.604 billion yuan, accounting for 10.62% of industrial sales revenue [1][2]. Strategic Developments - The acquisition of a 10% stake in Hutchison China MediTech for 995 million yuan strengthened the company's position and contributed over 1 billion yuan in profit [3]. - The company completed the acquisition, increasing its stake from 50% to 60%, transitioning from equity method accounting to subsidiary accounting [3]. - 2025 marked a pivotal year for innovation, with the approval of a first-class innovative drug for hypertension, and a pipeline of 59 new drug applications, including 47 innovative drugs [3]. Future Outlook - For 2026, the company aims to solidify its industrial foundation and enhance its commercial service platform, focusing on international expansion and AI technology applications [4]. - The operational strategy emphasizes quality improvement and innovation to seize industry opportunities, positioning the company as a leading player in the pharmaceutical sector [4].